Equities

Bonus BioGroup Ltd

BONS:TLV

Bonus BioGroup Ltd

Actions
IndustrialsConstruction and Materials
  • Price (ILa)10.90
  • Today's Change-0.300 / -2.68%
  • Shares traded1.58m
  • 1 Year change-27.33%
  • Beta1.6085
Data delayed at least 20 minutes, as of Nov 25 2024 10:44 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Bonus Biogroup Ltd, formerly Oceana Advanced Industries Ltd, is an Israel-based product-focused biotechnology company applying technology for supplying bone regeneration tissues. The Company is developing cell therapy products based on autologous and allogeneic bone implants that will enable efficient bone transplant and provide cellular-based bone replacement prosthetics for repairing bone lesions. It is targeting a worldwide market for the treatment of major disorders such as bone and cartilage related arthritis, osteoporosis, and various types of bones and joint trauma such as hip fractures and knee injuries, among others. On April 29, 2012, Bonus Bio Group Ltd fully acquired Bonus Therapeutic Ltd.

  • Revenue in ILS (TTM)0.00
  • Net income in ILS-29.19m
  • Incorporated1981
  • Employees58.00
  • Location
    Bonus BioGroup LtdMatamHAIFA 3190501IsraelISR
  • Phone+972 732067100
  • Fax+972 732067111
  • Websitehttps://bonus-bio.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Nextage Therapeutics Ltd1.02m-3.36m27.56m--------26.97-0.1057-0.10570.032-0.12931.58--10.32---553.86-188.94---423.7622.6033.33-351.17-2,486.19---65.46------17.9930.57------
Kadimastem Ltd0.00-9.68m53.30m32.00---------2.12-2.120.00-1.940.00-------129.59-155.33---1,831.12-----------3.113.31------47.14---50.73--
Matricelf Ltd0.00-13.66m63.81m----2.96-----0.8738-0.87380.001.340.00-------47.15---50.89--------------0.057-------10.77------
X T L Biopharmaceuticals Ltd1.68m-83.24m80.87m33.00--0.4222--48.13-0.378-0.3780.00760.15270.0192--0.701250,918.16-94.96-53.17-111.98-59.10---2.33-4,953.75-1,084.42----0.00---85.80---7.97---53.12--
DNA Group TR Ltd306.00k15.05m110.60m14.007.351.13--361.440.12220.12220.00250.79810.0033--1.4421,857.1416.35-23.5416.48-26.27----4,918.63-7,406.24----0.00---45.36--95.00------
BioLine RX Ltd43.14m-181.90m127.34m79.00--2.39--2.95-0.1882-0.18820.0430.04450.1939--6.40546,029.40-81.75-52.74-127.94-65.4355.84---421.69-3,501.791.05-519.430.4642-------142.93---50.72--
Bonus Biogroup Ltd0.00-29.19m134.31m58.00--8.72-----0.0718-0.07180.000.01320.00----0.00-64.14-76.10-74.97-97.19------------0.4106------26.29--19.30--
Compugen Ltd221.52m5.92m467.25m68.0074.702.12--2.110.0710.0712.482.500.6263--24.503,257,621.001.67-28.412.09-32.5784.5392.402.67-293.48--------346.1213.4544.34--1.71--
Data as of Nov 25 2024. Currency figures normalised to Bonus BioGroup Ltd's reporting currency: Israeli Shekel ILS

Institutional shareholders

0.02%Per cent of shares held by top holders
HolderShares% Held
Alumot Sprint Mutual Funds Management Ltd.as of 31 Jul 2024191.28k0.02%
Data from 31 Jul 2024 - 31 Jul 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.